News
The FDA accepted a supplemental application for Breyanzi to treat adults with relapsed or refractory marginal zone lymphoma ...
Zacks Investment Research on MSN15h
BMY Stock Trades Near 52-Week Low: Time to Buy or Sell?Share price of Bristol Myers Squibb (BMY) touched a 52-week low of $42.96 on July 31, post its second-quarter earnings ...
US FDA accepts for priority review Bristol Myers Squibb’s sBLA for Breyanzi to treat adult patients with relapsed or refractory MZL: Princeton, New Jersey Wednesday, August 6, 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback